Literature DB >> 29455519

A Self-Targeting, Dual ROS/pH-Responsive Apoferritin Nanocage for Spatiotemporally Controlled Drug Delivery to Breast Cancer.

Bin Du1,2,3, Shaona Jia1, Qinghui Wang1, Xiaoyu Ding1, Ying Liu1, Hanchun Yao1,2,3, Jie Zhou1,2,3.   

Abstract

In this study, an intelligent pH and ROS dual-responsive drug delivery system based on an apoferritin (AFt) nanocage was prepared. This therapeutic system can specifically self-target 4T1 breast cancer cells by exploiting L-apoferritin receptor SCARA 5, avoiding the nonspecific binding or aggregation of nanoparticles due to the chemical functionalization for targeting. The characteristics of AFt were utilized for the simultaneous delivery of anticancer drug doxorubicin (DOX) and photosensitizer rose bengal (RB). RB exhibited efficient reactive oxygen species (ROS) generation, which can be applied to photodynamic therapy. Meanwhile, the AFt nanocage was prone to undergoing peptide backbone cleavage when oxidized by ROS. Therefore, by combining the intrinsic pH-responsive property of AFt, the dual ROS/pH-responsive system was developed. The time and location of drug release can be controlled by the combination of internal and external stimulus, which avoids the incomplete drug release under single stimulus response. The drug release rate increased significantly (from 26.1% to 92.0%) under low-pH condition (pH 5.0) and laser irradiation. More DOX from AFt entered the nucleus and killed the tumor cells, and the cell inhibition rate was up to ∼83% (DOX concentration: 5 μg/mL) after 48 h incubation. In addition, the biodistribution and the in vivo antitumor efficacy (within 14 d treatment) of the nanosystem were investigated in 4T1 breast cancer BALB/c mice. The results indicated that the system is a promising therapeutic agent involving ROS/pH dual response, self-targeting, and chemo-photodynamic therapy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29455519     DOI: 10.1021/acs.biomac.8b00012

Source DB:  PubMed          Journal:  Biomacromolecules        ISSN: 1525-7797            Impact factor:   6.988


  12 in total

1.  Lysosomal escaped protein nanocarriers for nuclear-targeted siRNA delivery.

Authors:  Xiuping Cao; Xinxin Shang; Yingshu Guo; Xiaofei Zheng; Wenxin Li; Di Wu; Li Sun; Shanliang Mu; Chuanen Guo
Journal:  Anal Bioanal Chem       Date:  2021-03-26       Impact factor: 4.142

2.  Construction and Biological Evaluation of Multiple Modification Hollow Mesoporous Silicone Doxorubicin Nanodrug Delivery System.

Authors:  Mengru Hu; Wenjing Zhang; Weidong Chen; Yunna Chen; Qianqian Huang; Qianqian Bao; Tongyuan Lin; Lei Wang; Shantang Zhang
Journal:  AAPS PharmSciTech       Date:  2022-06-27       Impact factor: 3.246

3.  Highly Expressing SCARA5 Promotes Proliferation and Migration of Esophageal Squamous Cell Carcinoma.

Authors:  Kawuli Jumai; Tangjuan Zhang; Bingzhang Qiao; Julaiti Ainiwaer; Haiping Zhang; Zhichao Hou; Idris Awut; Madinyat Niyaz; Liwei Zhang; Ilyar Sheyhidin
Journal:  J Immunol Res       Date:  2022-06-17       Impact factor: 4.493

4.  Tuning C-Phycocyanin Photoactivity via pH-Mediated Assembly-Disassembly.

Authors:  Ying Li; Richard Gillilan; Alireza Abbaspourrad
Journal:  Biomacromolecules       Date:  2021-11-12       Impact factor: 6.978

5.  Soft and Condensed Nanoparticles and Nanoformulations for Cancer Drug Delivery and Repurpose.

Authors:  Wen Yang; Hanitrarimalala Veroniaina; Xiaole Qi; Pengyu Chen; Feng Li; Pu Chun Ke
Journal:  Adv Ther (Weinh)       Date:  2019-10-16

Review 6.  Bioengineered Ferritin Nanocarriers for Cancer Therapy.

Authors:  Xuanrong Sun; Yulu Hong; Yubei Gong; Shanshan Zheng; Dehui Xie
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

Review 7.  Human Pluripotent Stem Cell-Derived Cardiomyocytes for Assessment of Anticancer Drug-Induced Cardiotoxicity.

Authors:  Verena Schwach; Rolf H Slaats; Robert Passier
Journal:  Front Cardiovasc Med       Date:  2020-04-08

8.  TfR1 binding with H-ferritin nanocarrier achieves prognostic diagnosis and enhances the therapeutic efficacy in clinical gastric cancer.

Authors:  Xiaojing Cheng; Kelong Fan; Lin Wang; Xiangji Ying; Andrew J Sanders; Ting Guo; Xiaofang Xing; Meng Zhou; Hong Du; Ying Hu; Huirong Ding; Ziyu Li; Xianzi Wen; Wenguo Jiang; Xiyun Yan; Jiafu Ji
Journal:  Cell Death Dis       Date:  2020-02-05       Impact factor: 8.469

9.  tLyP-1 Peptide Functionalized Human H Chain Ferritin for Targeted Delivery of Paclitaxel.

Authors:  Yuanmeng Ma; Ruike Li; Yixin Dong; Chaoqun You; Shenlin Huang; Xun Li; Fei Wang; Yu Zhang
Journal:  Int J Nanomedicine       Date:  2021-02-04

10.  High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors.

Authors:  Elisabetta Falvo; Verena Damiani; Patrizio Giacomini; Michele Milella; Vincenzo De Laurenzi; Giulio Fracasso; Pierpaolo Ceci; Giamaica Conti; Federico Boschi; Katia Messana; Veronica Morea; Gianluca Sala
Journal:  J Exp Clin Cancer Res       Date:  2021-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.